CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or the "Company") today released a letter to shareholders from the Chairman of the Company's Board ...

CytoMed has generated the critical cell banks for the iPSC-derived hybrid of gamma delta T and Natural Killer cell technology and is currently undergoing process development into a potentially very ...

Fate Therapeutics uses iPSC and gene editing to offer scalable off-the-shelf therapies. Read more to see why I rate FATE ...

About Fate Therapeutics, Inc. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a ...

Personalized medicine advances as autologous cell therapy grows, leveraging refined cell collection, improved processing ...

Embryonic stem cells and induced pluripotent stem cells are pluripotent stem cells. Optimized lentiviral transduction enhances gene delivery in human iPSC-derived lung organoids, enabling advanced ...

STEM Potential supports you through years 10 and 12 with insightful lectures, subject-specific workshops and a non-residential summer school. STEM Potential is a multi-year programme of activities and ...

An investigator-initiated Phase 1/2 trial of CNTY-101, an investigational therapy, has been announced for the treatment of B-cell mediated autoimmune diseases, including systemic lupus erythematosus ...

This review summarized three groundbreaking approaches: islet organoids differentiated from Procr+ pancreatic progenitor cells, chemically induced pluripotent stem cells (CiPSCs), and endoderm stem ...

Scientists thereby presume that cancer stem cells (CSCs ... the undifferentiated and self-renewing state of cancer cells and inhibition of the HA-HIF-1 axis similarly reduces the CSC-like ...

Established guidelines for the management of chemotherapy-induced nausea and vomiting (CINV) currently recommend three main classes of drugs: 5-HT 3 receptor antagonists, NK 1 receptor antagonists ...

For the new therapy, these cells are derived from stem cells that originated from healthy adult donor tissue — called induced pluripotent stem cells (iPSCs) — to make therapeutic CAR-NK cells. These ...